Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 30;24(1):266.
doi: 10.1186/s12883-024-03691-3.

Response to letter to the editor regarding "Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries"

Angelo Antonini  1 , K Ray Chaudhuri  2 , Josefa Domingos  3   4 , Joohi Jimenez-Shahed  5 , Jack Wright  6 , Connie H Yan  7 , Ali Alobaidi  7 , Lars Bergmann  7 , Koray Onuk  7 , Linda Harmer  7 , Irene A Malaty  8
Affiliations

Response to letter to the editor regarding "Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries"

Angelo Antonini et al. BMC Neurol. .

Abstract

The 5-2-1 criteria was developed to facilitate the identification and referral of patients with Parkinson's Disease (PD) inadequately controlled by oral medications. The criterion was not developed to screen patients with PD for device-aided therapy eligibility. The robust design and validation of the 5-2-1 criteria minimizes over or inappropriate referrals, and supports physicians in the timely identification of patients with PD who may warrant further evaluation for treatment optimization. This response letter clarifies concerns raised by Moes et al.

Keywords: 5-2-1 criteria; Advanced Parkinson’s disease; Device-aided therapies; Patient identification; Screening performance.

PubMed Disclaimer

Conflict of interest statement

IAM has participated in research funded by AbbVie, Emalex, Neuroderm, Revance, and Sage but has no owner interest in any pharmaceutical company. She has consulted for Abbvie and received royalties from Robert Rose Publishers; KRC has received educational funding from UCB, and honoraria for sponsored symposiums from UCB, AbbVie, Britannia, US Worldmeds, Otsuka, Medtronic, Zambon and acted as a consultant for AbbVie, UCB, Britannia, Medtronic and Mundipharama; JJ-S has received consulting fees from Teva, Nuvelution, Bracket, Amneal, Revance, AbbVie, CNS Ratings, St. Jude Medical, Medtronic and research funding from Impax; JD declares no relevant conflict of interest to present study; CHY, AlA, KO, LB, and LH are employees of AbbVie and may own stocks/shares in the company; JW is an employee of Adelphi Real World, a consulting company that was hired by AbbVie to perform analyses on the Adelphi Disease Specific Programme database; AnA has received compensation for consultancy and speaker related activities from UCB, Boehringer Ingelheim, Britannia, AbbVie, Kyowa Kirin, Zambon, Bial, Neuroderm, Theravance Biopharma, Roche; he receives research support from Chiesi Pharmaceuticals, Lundbeck, Horizon 2020 - Grant 825785, Horizon2020 Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081, Cariparo Foundation. He serves as consultant for Boehringer Ingelheim for legal cases on pathological gambling.

Similar articles

See all similar articles

References

    1. Malaty IA, Martinez-Martin P, Chaudhuri KR, Odin P, Skorvanek M, Jimenez-Shahed J, et al. Does the 5-2-1 criteria identify patients with advanced Parkinson’s disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries. BMC Neurol. 2022;22(1):35. 10.1186/s12883-022-02560-1 - DOI - PMC - PubMed
    1. Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063–72. 10.1185/03007990802457040 - DOI - PubMed
    1. Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6(8):e010352. 10.1136/bmjopen-2015-010352 - DOI - PMC - PubMed
    1. Higgins V, Piercy J, Roughley A, Milligan G, Leith A, Siddall J, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371–80. 10.2147/DMSO.S120101 - DOI - PMC - PubMed
    1. Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018;34(12):2063–73. 10.1080/03007995.2018.1502165 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources